Genmab A (GMAB) Net Cash Flow (QoQ) (2020 - 2026)
Powered by 
Analysis
Genmab A (GMAB) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 87.98% |
| Sep 30, 2025 | 529.89% |
| Jun 30, 2025 | -137.66% |
| Mar 31, 2025 | -38.71% |
| Dec 31, 2024 | 1,522.51% |
| Sep 30, 2024 | 90.72% |
| Jun 30, 2024 | -398.04% |
| Mar 31, 2024 | -182.94% |
| Dec 31, 2023 | 3,633.34% |
| Mar 31, 2023 | 21,258.64% |
| Dec 31, 2022 | 120.04% |
| Dec 31, 2021 | -34.90% |
| Sep 30, 2021 | 109.75% |
| Jun 30, 2021 | -107.38% |
| Mar 31, 2021 | 22,051.43% |
| Dec 31, 2020 | -90.83% |